Shellie is an experienced toxicologist and scientific leader with more than fifteen years in both in vivo and in vitro testing and study design, medical-device biocompatibility, and laboratory quality-system management. Skilled in FDA requirements for alternative in vitro methods, she has led multidisciplinary teams delivering complex studies and regulatory submissions for global pharmaceutical clients as well as for Founder-led biotech ventures.

Shellie began her career in pharmaceutical research before moving into senior roles at Wickham Laboratories and Hoeford Research. There, she oversaw GxP programmes, validation of alternative test methods, and regulatory compliance. This experience gave her a clear view of how structure, quality, and communication determine the credibility and success of scientific work.

She is focused on bridging rigorous science with practical delivery – creating pathways that help research move from discovery to clinic with greater confidence and credibility.